Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction.
BACKGROUND
Satisfaction with information on medication is linked to adherence, but patients are often dissatisfied with information about medication. Information about treatment with fingolimod is important for MS patients since an active role in managing treatment is required from them. To facilitate optimal treatment initiation, a nurse-led patient education program on fingolimod was implemented in a Swiss MS center.


OBJECTIVE
To evaluate the impact of the evidence-based comprehensive patient education program on knowledge, self-efficacy and patient satisfaction.


METHODS
Knowledge gain, subjective perception of being informed about the new treatment, self-efficacy in handling it and satisfaction with the program were evaluated in a pretest-posttest design. Patient reported outcomes were collected before and after an educational session on the first-dose day at the MS Center in a consecutive sample of 98 people with MS. Data was analyzed descriptively, score comparisons were done by Wilcoxon tests, and associations were estimated with Spearman's correlation coefficient.


RESULTS
Knowledge increased significantly from pre- to posttest. Similarly, perception of being informed and self-efficacy increased significantly. Satisfaction with the program was high. Pretest-differences in knowledge concerning gender and marital status were balanced after the educational session. Results did not differ between patients with fingolimod as first treatment and those switching from other MS treatments. At posttest perception of being informed and self-efficacy were significantly related to satisfaction.


CONCLUSIONS
An evidence-based comprehensive treatment education program is suitable to satisfy MS patients' information needs at treatment initiation. It enhances short-term treatment knowledge and self-efficacy in handling a new treatment in daily life. MS Nurses can thus contribute to effective treatment education and potentially to medication safety and adherence.
Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. Electronic address: andrea.zimmer@usb.ch.
Andrea
A
Zimmer
Department of Special Clinics, University Hospital Basel, Hebelstrasse 2, 4031 Basel, Switzerland. Electronic address: cornelia.blaeuer@usb.ch.
Cornelia
C
Bläuer
Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. Electronic address: michael.coslovsky@usb.ch.
Michael
M
Coslovsky
Departments of Neurology and Biomedicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. Electronic address: ludwig.kappos@usb.ch.
Ludwig
L
Kappos
Departments of Neurology and Biomedicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. Electronic address: tobias.derfuss@usb.ch.
Tobias
T
Derfuss
D000328:Adult; D000368:Aged; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D055118:Medication Adherence / Q000523:psychology; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000523:psychology*; D010353:Patient Education as Topic / Q000379:methods*; D017060:Patient Satisfaction; D010465:Perception; D020377:Self Efficacy; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride
Medication information; Multiple sclerosis; Nurse-led; Patient education; Patient satisfaction; Self-efficacy